REVA Medical, Inc. ("REVA" or the "Company") completed its initial public offering of CDIs (CHESS Depository Interests) on December 17, 2010 and began trading on the Australian Securities Exchange ("ASX") on December 23, 2010, under the symbol "RVA." Ownership interests in REVA may be held in either CDIs or shares of common stock, but only CDIs may be traded on the ASX. Ten CDIs are equal to one share of common stock.
REVA is dedicated to developing minimally invasive medical devices that leverage the Company's proprietary biomaterial and stent technologies to improve the treatment of disease. Guided by a management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA's initial focus is the development and eventual commercialization of a proprietary drug-eluting bioresorbable coronary scaffold to treat coronary artery disease. REVA initiated a pilot human clinical trial of its ReZolve® scaffold in 2011, and a larger clinical trial of its anticipated commercial product, ReZolve2, was initiated in 2013.
REVA is headquartered in San Diego, California.